Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to a group of unintended messenger RNA (mRNA) transcripts that are silenced during RNA interference (RNAi) experiments designed to target Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1). When shRNA is used to knock down EIF4G1, the guide strand can incorporate into the RNA-induced silencing complex (RISC) and bind to other mRNAs with partial sequence complementarity, most commonly through the 'seed region' (nucleotides 2-8) in the 3' untranslated region (Jackson et al., 2003). This interaction leads to the degradation or translational inhibition of non-target genes, a phenomenon known as seed-mediated off-target effects (Birmingham et al., 2006). EIF4G1 itself is a critical scaffold protein in the eIF4F complex that facilitates the recruitment of the 40S ribosomal subunit to mRNA for protein synthesis (Sonenberg & Hinnebusch, 2009). Because EIF4G1 is frequently overexpressed in various cancers, it is a common subject of knockdown studies; however, off-target effects can confound results by inducing phenotypes, such as cell death, that are unrelated to EIF4G1 depletion (Sigoillot et al., 2012). These off-target events represent a significant technical challenge in drug discovery and functional genomics, necessitating the use of multiple independent shRNA sequences or rescue experiments to validate findings. Consequently, these mRNAs are not therapeutic targets themselves but are critical confounding factors in the development and validation of EIF4G1-targeted therapies.
Unintended gene silencing via the RNA-induced silencing complex (RISC) where the shRNA guide strand binds to mRNAs with partial sequence complementarity, typically mediated by the 5' seed region (nucleotides 2-8).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Off-target mRNAs with partial complementarity to the EIF4G1 shRNA guide strand.